Gapping up
In reaction to earnings/guidance:
- ANGO +10.1%, BIG +6.8%, RLGT +3.6%, PEB +2.9%, INFO +1.2%
M&A news:
- NOVS +16.6% (Novus Capital (publicly-traded special purpose acquisition company) and AppHarvest enter into business combination agreement)
- ORGS +16% (announces agreement to acquire Koligo Therapeutics)
- SOHU +15.3% (Sohu.com subsidiary Sogou (SOGO) enter merger agreement with Tencent (TCEHY))
- SOGO +2.7% (Sohu.com subsidiary Sogou (SOGO) enter merger agreement with Tencent (TCEHY))
- NBEV +2.4% (signed and closed a definitive agreement with Zachert Private Equity to sell its "Brands Within Reach" group and associated retail brands effectively immediately) .
Other news:
- GPMT +9.3% (declares dividend of $0.20/sh; provides business update)
- WINT +7.7% (FDA has accepted its Investigational New Drug (IND) application for a Phase 2 clinical trial studying lyo lucinactant in COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS) patients)
- SMMT +6.6% (higher after Mahkam Zanganeh disclosed 7.8% active stake)
- SRNE +5.5% (reports preclinical data for STI-1499 and STI-2020; demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates)
- BEDU +4.1% (announced that it entered into agreements to acquire 60% equity interests in Leti Camp Education)
- AERI +4% (announces acceptance of its investigational new drug application for AR-15512 (TRPM8 Agonist) eye drop for dry eye disease)
- DYN +3.9% (Citadel Advisors discloses 6.4% stake)
- SALT +3.3% (to sell a Kamsarmax vessel)
- DNLI +3.1% (BIIB discloses 11.16% stake in DNLI)
- VER +2.9% (provides Sept rent collection update)
- HTZ +2.5% (new CFO)
- GALT +2.5% (volatility continues ahead of its Investor Call - scheduled for today at 4:00 p.m. EDT)
- FCEL +2.5% (announces multiple project awards by the local Connecticut electric distribution companies, Eversource and United Illuminating, totaling 11.2 megawatts, as part of the state-sponsored Shared Clean Energy Facility program)
- BBIO +2.4% (BridgeBio Pharma and affiliate Origin Biosciences announce FDA acceptance of NDA for fosdenopterin)
- BLDP +2.2% (expands manufacturing capacity for membrane electrode assemblies)
- SNOW +1.6% (Berkshire Hathaway discloses 15.2% stake; Altimeter Capital discloses 13.27% stake)
- PRSC +1% (expands into Home Care Segment with accretive acquisition of Simplura Health Group for $575 mln)
Analyst comments:
- HSY +2.5% (upgraded to Outperform from Market Perform at BMO Capital)
- PK +2.4% (upgraded to Buy from Underperform at BofA Securities)
- RH +1.9% (upgraded to Outperform from Market Perform at Cowen)
- D +1.2% (upgraded to Overweight from Neutral at JP Morgan)
- SQ +1.2% (upgraded to Outperform from Peer Perform at Wolfe Research)
- STAY +1.1% (upgraded to Buy from Neutral at BofA Securities)
- EL +1% (upgraded to Neutral from Sell at Goldman)